Citius Pharmaceuticals

Citius Pharmaceuticals, Inc., founded with a mission to develop and commercialize first-in-class critical care products, operates as a late-stage biopharmaceutical company. The company focuses on anti-infectives in oncology, adjunct cancer care, stem cell therapy, and unique prescription products. Targeting the U.S. market, Citius aims to address unmet medical needs and improve patient outcomes through innovative therapeutic solutions.

Notable figures affiliated with Citius Pharmaceuticals include its founders who have invested $0.5 million into the company. The firm has achieved significant milestones, including the development of Mino-Lok®, which has a worldwide sales potential of $0.8 billion. With a diversified pipeline and a focus on critical care, Citius Pharmaceuticals has made a substantial impact in the biopharmaceutical industry, particularly in oncology and anti-infective therapies.